 Kura Oncology NASDAQ:KURA was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of ... 